AJG Co-Editor-in-Chief Paul Moayyedi, MD, FACG, on Noteworthy Biomarker Advances in Gastroenterology Unveiled in June Issue

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks
    Paul Moayyedi, MD, FACG

    Paul Moayyedi, MD, FACG

    Biomarker advances in gastroenterology are highlighted in a special June issue of The American Journal of Gastroenterology, which also provides new data on how these advances can help the clinician in a wide variety of gastrointestinal (GI) and liver diseases.

    The use of biomarkers in gastroenterology is especially important since GI and liver diseases present with a wide variety of symptoms and these often have poor diagnostic accuracy.  We often have to rely on imaging or endoscopy to distinguish between organic and functional GI diseases but this can be expensive and invasive and does not help with the differentiation of functional GI diseases. But even when organic GI or liver disease is diagnosed, symptoms can have poor correlation with severity of underlying disease so follow up of these patients can be challenging.

    As you know, biomarkers (short for biological markers) detect diagnostically useful substances in the blood, urine, tissue or stool and can be powerful tools for clinicians to monitor organic disease. Biomarkers also offer the possibility of subdividing functional GI disease into clinically useful subgroups that may respond differently to therapy or may have a different prognosis.

    Whatever your interest, this issue of AJG is sure to give you information on biomarkers that will change your clinical practice and benefit your GI patients.

    Some highlights of the June biomarker issue I found noteworthy include:

    • Articles on how fecal calprotectin (FP) and lactoferrin can be used as an early marker of the development of pouchitis as well as a study describing the utility of FP in asymptomatic post-operative recurrence of Crohn’s disease. Read full study

     

    •  American Association for the Study of Liver Diseases and the European Association for the Study of the Liver guidelines have moved away from using alpha-fetoprotein (AFP) in cirrhosis surveillance programs but data from the biomarker AJG issue suggests that AFP does add useful information to ultrasound in diagnosing hepatocellular carcinoma.   Read full study

     

    • An interesting study suggests Wisteria floribunda agglutinin positive Mac-2 binding protein is a strong predictor of clinical outcome in primary biliary cirrhosis and is superior to all other non-invasive markers in predicting fibrosis stage. Read full study

     

     

    • Fascinating data on the identification of gluten-degrading Pseudomona aeruginosa from human feces. The authors identified an enzyme pseudolysin B produced by these bacteria that degrades gluten and could potentially render it non-immunogenic. This could be used as a marker to determine subjects that are at low risk of celiac disease despite having the genetic predisposition, and also raises intriguing possibilities for new therapies for cpseudolysin B. Read full study

     

    • A prospective study of Eosinophilic esophagitis (EoE) cases and non-EoE controls who underwent endoscopy for reflux of dysphagia , found that none of the 14 serum biomarkers examined, which were a range of proinflammatory cytokines, eosinophil chemokines, and eosinophil granules, had utility for either diagnosis or monitoring of EoE. Read full study     Read author insight  Watch Video with Author Insight

    See full Table of Contents for the AJG June Biomarker Issue

    AJG Co-Editor-in-Chief, Paul Moayyedi, MD, FACG

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks